62029-63-4

Usage

Uses

Used in Pharmaceutical Research and Development:
2,5,7-Tris-tert-butyl-L-tryptophan is used as a research compound for investigating the biological activity of tryptophan derivatives. Its unique structure allows scientists to explore the effects of structural modifications on the amino acid's interactions within biological systems, potentially leading to the discovery of new therapeutic agents.
Used in Biochemical Process Studies:
In the field of biochemistry, 2,5,7-Tris-tert-butyl-L-tryptophan is utilized as a tool to study the role of tryptophan in various biochemical processes. 2,5,7-Tris-tert-butyl-L-tryptophan's modified properties may provide insights into the mechanisms of tryptophan involvement in cellular functions and contribute to a deeper understanding of its role in health and disease.
Used in Drug Development:
2,5,7-Tris-tert-butyl-L-tryptophan is employed as a potential drug candidate in the development of novel therapeutics. Its unique structure and properties may offer advantages in terms of stability, bioavailability, or target specificity, making it a promising starting point for the design of new medications targeting specific biological pathways or receptors.
Used in Chemical Synthesis:
In the chemical synthesis industry, 2,5,7-Tris-tert-butyl-L-tryptophan may be used as an intermediate or building block in the synthesis of more complex molecules or drug candidates. Its unique structure can be further modified or functionalized to create new compounds with tailored properties for various applications.
Used in Material Science:
2,5,7-Tris-tert-butyl-L-tryptophan's unique chemical and physical properties may also find applications in material science. 2,5,7-Tris-tert-butyl-L-tryptophan could be incorporated into the development of new materials with specific properties, such as improved stability, biocompatibility, or responsiveness to environmental stimuli, for use in various industries, including electronics, coatings, or medical devices.

Upstream product

• 73-22-3 L-Tryptophan 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 78654-82-7 Boc-Ttb-OH 

Relevant academic research and scientific papers

Synthetic antimicrobial peptidomimetics with therapeutic potential

A series of synthetic antimicrobial peptidomimetics (SAMPs) have been prepared and found to be highly active against several Gram-negative and Gram-positive bacterial strains. These derivatives comprise the minimal structural requirements for cationic antimicrobial peptides and showed high selectivity for Gram-negative and/or Gram-positive bacteria compared to human red blood cells. We have found that SAMPs share many of the attractive properties of cationic antimicrobial peptides inasmuch that a representative SAMP was found to insert into the bilayers of large unilamellar vesicles, permeabilized both the outer and cytoplasmic membrane of Escherichia coli ML-35p, and displayed an extremely rapid bacterial killing for Staphylococcus aureus. However, while antimicrobial peptides are prone to proteolytic degradation, high in vitro stability in human blood plasma was shown for SAMPs. A combination of high antibacterial activity against methicillin-resistant staphylococci and low toxicity against human erythrocytes makes these molecules promising candidates for novel antibacterial therapeutics.

Dendrimeric peptides, pharmaceutical compositions and methods of using the same

Novel peptide compounds and pharmaceutical compositions thereof are disclosed that have a formula represented by the following formula (I) wherein L1, L2, L3, Z, R1, R2, R4 and R5 are as described herein. The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provided by standard antibiotics.

Inhibition of tumor growth

The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of p

Bioactive peptides

The present invention provides a modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and which has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin sequence, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing such peptides, pharmaceutical compositions containing such peptides and use of the peptides as medicaments, particularly as antibacterials or anti-tumoural agents.